Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarker
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 16 Nov 2018 Status has been changed to active, no longer recruiting.
- 30 Jun 2018 Status changed from recruiting to completed.
- 03 Aug 2017 New trial record